Lyme Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Lyme Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

The Lyme disease market reached a value of US$ 594.1 Million across the top 7 markets (US, EU4, UK, and Japan) in 2023. Looking forward, IMARC Group expects the top 7 markets to reach US$ 1,181.7 Million by 2034, exhibiting a growth rate (CAGR) of 6.45% during 2024-2034.

The Lyme disease market has been comprehensively analyzed in IMARC's new report titled "Lyme Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Lyme disease is a vector-borne illness caused by a bacteria called Borrelia burgdorferi. This condition is transmitted to humans by the bites of infected ticks of the species Ixodes. The disease is usually characterized by an expanding, non-painful red rash, named erythema migrans, which develops at the site of the tick bite after around a week. The common symptoms associated with the ailment include rash, fever, headache, extreme tiredness, swollen lymph nodes, etc. In severe cases, patients may also experience joint pain, impaired ability to move one or both sides of the face, neck stiffness, headaches, memory difficulty, or heart palpitations. The diagnosis of this disorder typically involves a combination of an objective physical examination, a review of the patient's medical history for possible exposure to infected ticks, and laboratory investigations. A blood antibody test using enzyme-linked immunosorbent assay (ELISA) and western blot is primarily performed to diagnose Lyme disease. The healthcare provider may also recommend polymerase chain reaction (PCR) tests to detect the presence of bacterial genetic material in the body.

The rising cases of tick-borne diseases owing to the increasing tick exposure through outside activities, such as gardening, hunting, hiking, etc., are primarily driving the Lyme disease market. Additionally, the widespread adoption of antibiotics and nonsteroidal anti-inflammatory drugs to help relieve pain and reduce inflammation associated with the ailment is further propelling the market growth. Moreover, the emerging popularity of advanced diagnostic tests, including T-Detect Lyme, which identifies an immune response by activated T-cells against bacteria to provide early disease diagnosis, is acting as another significant growth-inducing factor. Apart from this, the rising usage of non-pharmaceutical interventions, such as cognitive behavioral therapy and acupuncture, to help improve functional disability and cope with the psychological effects of the condition is also augmenting the market growth. Furthermore, the escalating demand for mesenchymal stem cell therapy owing to its potent immunomodulatory and anti-inflammatory properties, which can reduce the severity of underlying symptoms and promote tissue repair, is creating a positive outlook for the market. Besides this, the increasing utilization of immunomodulatory therapies, including low-dose naltrexone and immune-modulating peptides, to regulate the immune system and enhance its ability to fight the infection is expected to drive the Lyme disease market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the Lyme disease market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for Lyme disease and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Lyme disease market in any manner.

Recent Developments
In December 2023, Pfizer Inc. and Valneva SE declared the completion of recruitment for the Phase 3 clinical trial Vaccine Against Lyme for Outdoor Recreationists (VALOR) (NCT05477524) for Lyme disease vaccine candidate VLA15. The trial expands upon previous positive Phase 1 and 2 trial outcomes, and it includes both pediatric and adult participants. The objective is to determine the efficacy, lot consistency, safety, and immunogenicity of VLA15.
In September 2023, Penn Medicine developed an mRNA vaccine against Borrelia burgdorferi, the bacteria that causes Lyme disease. A pre-clinical study revealed that the experimental vaccine shows potential in reducing the incidence of Lyme disease.
In April 2023, Moderna announced new vaccine candidates, mRNA-1982 and mRNA-1975, which represented the company's first application of its mRNA technology to bacterial pathogens, including Lyme disease. mRNA-1982 is intended to elicit antibodies specific for Borrelia burgdorferi, whereas mRNA-1975 is designed to stimulate antibodies specific for the four primary Borrelia species that cause the disease.

Key Highlights:
Lyme disease is the most widespread tick-borne infection in the Northern Hemisphere, accounting for 70% of all reported tick-borne disorders.
The Centers for Disease Prevention and Control currently predict that up to 476,000 people in the United States contract Lyme disease each year through the bite of a deer tick.
Approximately 20% of persons may develop Post-treatment Lyme disease syndrome (PTLDS), which is the persistence of some Lyme symptoms following antibiotic therapy.
Central Europe had the highest infection rate, with 21% of the population affected; eastern Asia was second at 16%, western Europe followed that at 13.5%.
People living in rural regions were at a larger risk than those living in urban areas, with 12.6% of positive tests coming from rural populations and 8.1% from urbanites.

Drugs:
Ceftin tablets are used to treat adult and pediatric patients (aged 13 and older) affected by early Lyme disease caused by susceptible Borrelia burgdorferi strains. It works by binding to certain proteins within the bacterial cell wall, preventing the third and final step of bacterial cell wall development. Cell lysis is then induced by bacterial cell wall autolytic enzymes known as autolysins.

VLA15 is an investigational Lyme disease vaccine candidate developed by Pfizer and Valneva. This experimental multivalent protein subunit vaccine utilizes a well-established mechanism of action for a Lyme disease vaccine by targeting the outer surface protein A (OspA) of Borrelia burgdorferi, the bacteria that cause Lyme disease.

CT38 is a strong, short-lived peptide agonist that targets CRFR2. It is entirely composed of naturally occurring amino acids. A Phase 1 clinical investigation was conducted on both animals and healthy humans. These investigations have defined CT38's safety profile in people, demonstrating that it only lasts a few hours in the body.


Time Period of the Study

Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the Lyme disease market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the Lyme disease market
Reimbursement scenario in the market
In-market and pipeline drugs

Competitive Landscape:
This report also provides a detailed analysis of the current Lyme disease marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.


Key Questions Answered in this Report:
Market Insights

How has the Lyme disease market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the Lyme disease market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the Lyme disease market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of Lyme disease across the seven major markets?
What is the number of prevalent cases (2018-2034) of Lyme disease by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of Lyme disease by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with Lyme disease across the seven major markets?
What is the size of the Lyme disease patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of Lyme disease?
What will be the growth rate of patients across the seven major markets?

Lyme Disease: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for Lyme disease drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Lyme disease market?
What are the key regulatory events related to the Lyme disease market?
What is the structure of clinical trial landscape by status related to the Lyme disease market?
What is the structure of clinical trial landscape by phase related to the Lyme disease market?
What is the structure of clinical trial landscape by route of administration related to the Lyme disease market?